Anti-CXCR4-dasatinib ADC (ADC-W-520)

This ADC product is comprised of an anti-CXCR4 monoclonal antibody conjugated via a linker to dasatinib.

Alternative Names
CXCR4; chemokine (C-X-C motif) receptor 4; FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; LAP-3; LESTR; NPY3R; NPYRL; HSY3RR; NPYY3R; D2S201E; C-X-C chemokine receptor type 4; fusin; CD184 antigen; SDF-1 receptor; LPS-associated protein 3; neuropeptide Y rece

Overview
This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Description
Dasatinib, also known as BMS-354825, is a cancer drug. It is an oral Bcr-Abl tyrosine kinase inhibitorand Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Name:

*Phone:

*E-mail Address:

*Products or Services Interested:

Company/Institution

Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
USA

Tel:
Fax:
Email:
Europe

Tel:
Email:
Germany

Tel:
Email: